-
Mutation analysis of circadian clock gene BMAL1 in 21 Pakistani congenital cataract families
Udita Bagchi, Shazia Micheal, Sorath Noorani Siddiqui, Muhammad Imran Khan, Jacoline B Ten Brink, MariePaule Felder-Schmittbuhl and Arthur A Bergen
Short Communication: Clinical Investigation
-
Mutation analysis of circadian clock gene BMAL1 in 21 Pakistani congenital cataract families
Udita Bagchi, Shazia Micheal, Sorath Noorani Siddiqui, Muhammad Imran Khan, Jacoline B Ten Brink, MariePaule Felder-Schmittbuhl and Arthur A Bergen
Short Communication: Clinical Investigation
-
Mutation analysis of circadian clock gene BMAL1 in 21 Pakistani congenital cataract families
Udita Bagchi, Shazia Micheal, Sorath Noorani Siddiqui, Muhammad Imran Khan, Jacoline B Ten Brink, MariePaule Felder-Schmittbuhl and Arthur A Bergen
Short Communication: Clinical Investigation
-
Mutation analysis of circadian clock gene BMAL1 in 21 Pakistani congenital cataract families
Udita Bagchi, Shazia Micheal, Sorath Noorani Siddiqui, Muhammad Imran Khan, Jacoline B Ten Brink, MariePaule Felder-Schmittbuhl and Arthur A Bergen
Short Communication: Clinical Investigation
-
Mutation analysis of circadian clock gene BMAL1 in 21 Pakistani congenital cataract families
Udita Bagchi, Shazia Micheal, Sorath Noorani Siddiqui, Muhammad Imran Khan, Jacoline B Ten Brink, MariePaule Felder-Schmittbuhl and Arthur A Bergen
Short Communication: Clinical Investigation
-
Mutation analysis of circadian clock gene BMAL1 in 21 Pakistani congenital cataract families
Udita Bagchi, Shazia Micheal, Sorath Noorani Siddiqui, Muhammad Imran Khan, Jacoline B Ten Brink, MariePaule Felder-Schmittbuhl and Arthur A Bergen
Short Communication: Clinical Investigation
-
Pooling of lupus can "catch" early skin cancerous: "Rapid Progression in DNA Damage"
Rahul Hajare
Commentary: Clinical Investigation
-
Pooling of lupus can "catch" early skin cancerous: "Rapid Progression in DNA Damage"
Rahul Hajare
Commentary: Clinical Investigation
-
Pooling of lupus can "catch" early skin cancerous: "Rapid Progression in DNA Damage"
Rahul Hajare
Commentary: Clinical Investigation
-
Pooling of lupus can "catch" early skin cancerous: "Rapid Progression in DNA Damage"
Rahul Hajare
Commentary: Clinical Investigation
-
Pooling of lupus can "catch" early skin cancerous: "Rapid Progression in DNA Damage"
Rahul Hajare
Commentary: Clinical Investigation
-
Pooling of lupus can "catch" early skin cancerous: "Rapid Progression in DNA Damage"
Rahul Hajare
Commentary: Clinical Investigation
-
New approaches to the design of clinical trials in idiopathic pulmonary fibrosis
Stefania Cerri, Cinzia Del Giovane, Sara Balduzzi, Francesco Soncini, Antonia Sdanganelli, Luca Richeldi
News and Views: Clinical Investigation
-
New approaches to the design of clinical trials in idiopathic pulmonary fibrosis
Stefania Cerri, Cinzia Del Giovane, Sara Balduzzi, Francesco Soncini, Antonia Sdanganelli, Luca Richeldi
News and Views: Clinical Investigation
-
New approaches to the design of clinical trials in idiopathic pulmonary fibrosis
Stefania Cerri, Cinzia Del Giovane, Sara Balduzzi, Francesco Soncini, Antonia Sdanganelli, Luca Richeldi
News and Views: Clinical Investigation
-
New approaches to the design of clinical trials in idiopathic pulmonary fibrosis
Stefania Cerri, Cinzia Del Giovane, Sara Balduzzi, Francesco Soncini, Antonia Sdanganelli, Luca Richeldi
News and Views: Clinical Investigation
-
New approaches to the design of clinical trials in idiopathic pulmonary fibrosis
Stefania Cerri, Cinzia Del Giovane, Sara Balduzzi, Francesco Soncini, Antonia Sdanganelli, Luca Richeldi
News and Views: Clinical Investigation
-
New approaches to the design of clinical trials in idiopathic pulmonary fibrosis
Stefania Cerri, Cinzia Del Giovane, Sara Balduzzi, Francesco Soncini, Antonia Sdanganelli, Luca Richeldi
News and Views: Clinical Investigation
-
Emerging clinical evidence in the treatment of eosinophilic esophagitis
CD Parmar , SE Attwood
Review: Clinical Trail Outcomes: Clinical Investigation
-
Emerging clinical evidence in the treatment of eosinophilic esophagitis
CD Parmar , SE Attwood
Review: Clinical Trail Outcomes: Clinical Investigation
-
Emerging clinical evidence in the treatment of eosinophilic esophagitis
CD Parmar , SE Attwood
Review: Clinical Trail Outcomes: Clinical Investigation
-
Emerging clinical evidence in the treatment of eosinophilic esophagitis
CD Parmar , SE Attwood
Review: Clinical Trail Outcomes: Clinical Investigation
-
Emerging clinical evidence in the treatment of eosinophilic esophagitis
CD Parmar , SE Attwood
Review: Clinical Trail Outcomes: Clinical Investigation
-
Emerging clinical evidence in the treatment of eosinophilic esophagitis
CD Parmar , SE Attwood
Review: Clinical Trail Outcomes: Clinical Investigation
-
Perspective on Adaptive Designs: 4 years European Medicines Agency reflection paper, 1 year draft US FDA guidance: where are we now?
Brenda Gaydos, Armin Koch, Frank Miller, Martin Posch, Marc Vandemeulebroecke, Sue-Jane Wang
Interview: Clinical Investigation
-
Perspective on Adaptive Designs: 4 years European Medicines Agency reflection paper, 1 year draft US FDA guidance: where are we now?
Brenda Gaydos, Armin Koch, Frank Miller, Martin Posch, Marc Vandemeulebroecke, Sue-Jane Wang
Interview: Clinical Investigation
-
Perspective on Adaptive Designs: 4 years European Medicines Agency reflection paper, 1 year draft US FDA guidance: where are we now?
Brenda Gaydos, Armin Koch, Frank Miller, Martin Posch, Marc Vandemeulebroecke, Sue-Jane Wang
Interview: Clinical Investigation
-
Perspective on Adaptive Designs: 4 years European Medicines Agency reflection paper, 1 year draft US FDA guidance: where are we now?
Brenda Gaydos, Armin Koch, Frank Miller, Martin Posch, Marc Vandemeulebroecke, Sue-Jane Wang
Interview: Clinical Investigation
-
Perspective on Adaptive Designs: 4 years European Medicines Agency reflection paper, 1 year draft US FDA guidance: where are we now?
Brenda Gaydos, Armin Koch, Frank Miller, Martin Posch, Marc Vandemeulebroecke, Sue-Jane Wang
Interview: Clinical Investigation
-
Perspective on Adaptive Designs: 4 years European Medicines Agency reflection paper, 1 year draft US FDA guidance: where are we now?
Brenda Gaydos, Armin Koch, Frank Miller, Martin Posch, Marc Vandemeulebroecke, Sue-Jane Wang
Interview: Clinical Investigation
-
Assessment of suicidal ideation and behavior in clinical trials: challenges & controversies
Glenn Melvin
Clinical Trail Perspective: Clinical Investigation
-
Assessment of suicidal ideation and behavior in clinical trials: challenges & controversies
Glenn Melvin
Clinical Trail Perspective: Clinical Investigation
-
Assessment of suicidal ideation and behavior in clinical trials: challenges & controversies
Glenn Melvin
Clinical Trail Perspective: Clinical Investigation
-
Assessment of suicidal ideation and behavior in clinical trials: challenges & controversies
Glenn Melvin
Clinical Trail Perspective: Clinical Investigation
-
Assessment of suicidal ideation and behavior in clinical trials: challenges & controversies
Glenn Melvin
Clinical Trail Perspective: Clinical Investigation
-
Assessment of suicidal ideation and behavior in clinical trials: challenges & controversies
Glenn Melvin
Clinical Trail Perspective: Clinical Investigation
-
Pediatric drug development: unmet medical needs and opportunities for collaboration between industry, academia and the US FDA
Lisa Mathis,Hong Vu, Andrew E Mulberg
: Clinical Investigation
-
Pediatric drug development: unmet medical needs and opportunities for collaboration between industry, academia and the US FDA
Lisa Mathis,Hong Vu, Andrew E Mulberg
: Clinical Investigation
-
Pediatric drug development: unmet medical needs and opportunities for collaboration between industry, academia and the US FDA
Lisa Mathis,Hong Vu, Andrew E Mulberg
: Clinical Investigation
-
Pediatric drug development: unmet medical needs and opportunities for collaboration between industry, academia and the US FDA
Lisa Mathis,Hong Vu, Andrew E Mulberg
: Clinical Investigation
-
Pediatric drug development: unmet medical needs and opportunities for collaboration between industry, academia and the US FDA
Lisa Mathis,Hong Vu, Andrew E Mulberg
: Clinical Investigation
-
Pediatric drug development: unmet medical needs and opportunities for collaboration between industry, academia and the US FDA
Lisa Mathis,Hong Vu, Andrew E Mulberg
: Clinical Investigation
-
Current evidence for the treatment of invasive fungal infections in immunocompromised patients
Jutta Auberger, Cornelia Lass-Flori
Review Article: Clinical Investigation
-
Current evidence for the treatment of invasive fungal infections in immunocompromised patients
Jutta Auberger, Cornelia Lass-Flori
Review Article: Clinical Investigation
-
Current evidence for the treatment of invasive fungal infections in immunocompromised patients
Jutta Auberger, Cornelia Lass-Flori
Review Article: Clinical Investigation
-
Current evidence for the treatment of invasive fungal infections in immunocompromised patients
Jutta Auberger, Cornelia Lass-Flori
Review Article: Clinical Investigation
-
Current evidence for the treatment of invasive fungal infections in immunocompromised patients
Jutta Auberger, Cornelia Lass-Flori
Review Article: Clinical Investigation
-
Current evidence for the treatment of invasive fungal infections in immunocompromised patients
Jutta Auberger, Cornelia Lass-Flori
Review Article: Clinical Investigation
-
Tocilizumab for rheumatoid arthritis: results of the Phase III clinical trial program
Javier Rueda, Miguel A Gonzlez-Gay, Ricardo Blanco
Review Article: Clinical Investigation
-
Tocilizumab for rheumatoid arthritis: results of the Phase III clinical trial program
Javier Rueda, Miguel A Gonzlez-Gay, Ricardo Blanco
Review Article: Clinical Investigation
-
Tocilizumab for rheumatoid arthritis: results of the Phase III clinical trial program
Javier Rueda, Miguel A Gonzlez-Gay, Ricardo Blanco
Review Article: Clinical Investigation
-
Tocilizumab for rheumatoid arthritis: results of the Phase III clinical trial program
Javier Rueda, Miguel A Gonzlez-Gay, Ricardo Blanco
Review Article: Clinical Investigation
-
Tocilizumab for rheumatoid arthritis: results of the Phase III clinical trial program
Javier Rueda, Miguel A Gonzlez-Gay, Ricardo Blanco
Review Article: Clinical Investigation
-
Tocilizumab for rheumatoid arthritis: results of the Phase III clinical trial program
Javier Rueda, Miguel A Gonzlez-Gay, Ricardo Blanco
Review Article: Clinical Investigation